COVID-19 Nigeria Update Today

Nigeria has recorded an additional 490 cases of COVID-19 in the last 24 hours.

Lagos tips the list with 142 cases, followed by the Federal Capital Territory (FCT) with 60. Others are Bayelsa-54, Rivers-39, Delta-37, Oyo-30, Kaduna-26, Imo-23, Enugu-19, Kwara-17, Gombe-11, Ondo-10, Bauchi-8, Ogun-7, Borno-6, and Benue with one case.

Out of the 1 17,148 confirmed cases, 5,623 patients have been discharged with 455 deaths recorded.

https://platform.twitter.com/widgets.js

READ: Nigeria News Headlines June 17 2020

Confirmed Cases by State

States AffectedNo. of Cases (Lab Confirmed)No. of Cases (on admission)No. DischargedNo. of Deaths
Lagos7,4616,0521,302107
FCT1,32491038628
Kano1,15844566350
Rivers63136224425
Edo62044515025
Oyo6053552428
Ogun57430525514
Kaduna47219227010
Borno44512229330
Gombe44127315612
Bauchi43017224711
Katsina41415923322
Jigawa3171331786
Delta3172247617
Nasarawa177103686
Abia173153200
Kwara16866984
Plateau168571065
Ebonyi16278840
Imo159135213
Sokoto1321510314
Bayelsa8655283
Ondo8238359
Zamfara760715
Enugu7644275
Anambra6632259
Niger6634311
Kebbi6629316
Yobe552458
Osun505414
Akwa Ibom4828182
Adamawa421374
Benue3625110
Ekiti3010182
Taraba188100
Kogi3300

Dexamethsaone not validated by WHO –

The Nigeria Centre for Disease Control (NCDC) has said that it is aware of recent outcomes from a UK-Government funded clinical trial for COVID-19.

The UK Prime Minister, Boris Johnson had described the drug, Dexamethasone as the life saver for now in the fight against the deadly virus.

The results support the use of Dexamethsaone as a possible treatment to reduce the risk of death among COVID-19 patients, who require oxygen or mechanical ventilation.

But the government agency said that that the Government of Nigeria has not validated or approved any treatment for COVID-19.

“In addition, the use of Dexamethasone for COVID-19 treatment has not been validated by the World Health Organisation (WHO).

“We are aware of ongoing clinical trials conducted by scientists in the UK and will work with our sister agencies to evaluate this emerging data on the use of Dexamethasone.

“We will inform the general public on outcomes following scientific review and validation,” it said.

Leave a Reply

Your email address will not be published. Required fields are marked *